Camp Lejeune Trial Verdict Pending: Mousser Case Ends in Three Days as October 30 Settlement Target Passes

There is no Camp Lejeune trial verdict yet: the first case tried under the Camp Lejeune Justice Act, Mousser v. United States, ended on Wednesday, October 28, 2026 after three days of evidence in Elizabeth City, North Carolina, and Judge Terrence W. Boyle has not said when he will rule. Two days later the court's October 30 target for a global settlement framework passed with no deal announced, leaving roughly 408,000 administrative claimants waiting on two things at once — a written judgment in one Marine's kidney cancer case and a negotiated structure for everyone else.

The trial was short, but the record it produced is not small. Former Marine Frank Mousser asked for nearly $1.2 million in economic damages plus compensation for pain and suffering. The Justice Department asked the court to find that he had not proved the water caused his cancer at all, and, if he had, to shrink any award by the value of benefits the government already pays or will pay him. Those two positions — causation and offsets — are the questions on which every Camp Lejeune claim is priced, which is why the first Camp Lejeune trial verdict, whenever it comes, will be read far beyond one courtroom.

This article explains what happened in the trial, what each side asked for, how and when Judge Boyle is likely to decide, what the lapse of the October 30 target means, and what comes next, including the second kidney cancer trial set for November 9.

Is there a verdict in the first Camp Lejeune trial?

No. As of November 2, 2026, there is no verdict in the first Camp Lejeune trial, and no timeline has been announced for Judge Boyle's decision. Because the case was tried to the judge rather than a jury, there is no moment at which a verdict is read in court; the outcome will arrive as a written decision containing findings of fact and conclusions of law.

That is the single most common misunderstanding in early coverage and search results. The phrase "Camp Lejeune trial verdict" suggests a jury returning to the box at the end of the evidence. In February 2024 the four judges of the Eastern District of North Carolina held that the Camp Lejeune Justice Act does not waive the United States' sovereign immunity from jury trials, and the Supreme Court declined to take up the question in 2025. Every Camp Lejeune trial, including this one, is therefore a bench trial. The judge is both fact-finder and decision-maker, and the decision comes when he is ready to issue it.

Public radio coverage on October 29, carried by Public Radio East, WFAE, WUNC and WHQR, reported that the trial began Monday in Elizabeth City, concluded Wednesday, and that Boyle will determine whether the plaintiff's illness was caused by the water contamination and, if so, what damages to award. None of that coverage, and none of the subsequent reporting reviewed for this article, identified a ruling date.

One further detail sits on the docket without an explanation. The Lawsuit Information Center's litigation log reports a docket entry on October 27, 2026 concerning a motion for judgment on partial findings — the mid-trial device a party uses in a bench trial to ask the court to rule against the other side on an issue before all the evidence is in. The log says the outcome of that ruling is not known. It is reasonable to assume the trial was not ended by it, because the evidence continued into October 28, but whether the court denied the motion, deferred it, or granted it on a narrow issue has not been reported.

How did the first Camp Lejeune trial unfold?

The first Camp Lejeune trial ran from Monday, October 26 to Wednesday, October 28, 2026 — three trial days — before Judge Boyle in the federal courthouse in Elizabeth City, one of the Eastern District's divisional seats. That is at the short end of the range the parties had forecast. Earlier in the litigation, plaintiffs estimated a Track 1 case could be tried in two to three days, while the government estimated about two weeks. The plaintiffs' estimate proved closer.

Three features explain the pace.

The judge already knows the science. The Eastern District has managed the Camp Lejeune docket since 2023, and the four judges assigned to it have ruled on the standard of causation, on expert admissibility under Rule 702, on the use of the Agency for Toxic Substances and Disease Registry (ATSDR) water models, and on offsets. Much of what would take days to explain to a jury — how the Hadnot Point and Tarawa Terrace systems were contaminated, what the ATSDR models do, what the epidemiology of trichloroethylene (TCE) shows — is already in the court's head.

The issues were narrowed before trial. Mousser is one of 25 Track 1 Trial Plaintiffs, five each for kidney cancer, bladder cancer, leukemia, non-Hodgkin lymphoma and Parkinson's disease. As this newsroom has explained, Track 1 plaintiffs waived claims for diseases outside their track, so Mousser is a single-disease case. His presence at the base from 1982 to 1986, inside the statute's August 1, 1953 to December 31, 1987 window, was not seriously contested. The fight was dose, diagnosis, causation and damages.

Bench trials move faster. There is no jury selection, no jury instructions conference, fewer sidebar disputes over what the fact-finder may hear, and greater latitude for written submissions. Judges often receive direct testimony of experts in written form or rely on deposition designations, and can take evidence subject to later rulings on admissibility.

Roll Call's October 29 report, syndicated by several regional papers, quoted a plaintiffs' lawyer who called the trial "almost like they had to finally set up a trial, just for purposes of showing that the litigation is moving." That captures a widely held view on the claimant side: four years after the statute passed, the trial's practical value lies less in Mousser's individual result than in breaking the logjam.

What did the government argue in the first Camp Lejeune trial?

The government argued that Frank Mousser cannot establish either general or specific causation between his exposure to Camp Lejeune water and his kidney cancer, according to Roll Call and AboutLawsuits reporting on the Justice Department's motion to dismiss. In other words, it contested both whether the water at the doses involved can cause his type of cancer and whether it caused his.

The pretrial record and trial coverage show the defense built on four connected points.

1. Time away from the base. Roll Call reported that the government's motion says Mousser "spent significant time away from Camp Lejeune" while stationed there between 1982 and 1986. That is a dose argument in personal form: a Marine assigned to the base but deployed, training elsewhere, or living off-base for long periods drank less of the contaminated water than his service dates alone suggest.
2. Dose from the models. In motions filed October 19, the Justice Department attacked the use of the ATSDR historical water models to estimate an individual's intake, arguing they can describe population exposure but cannot establish how much contaminated water one Marine consumed.
3. Diagnosis. The government has distinguished between two kinds of cancer in the kidney region — upper tract urothelial carcinoma, which arises in the lining of the renal pelvis or ureter, and renal cell carcinoma, the more common cancer of kidney tissue — arguing that the TCE evidence is strongest for the latter and that Mousser's diagnosis is the former. WUNC's coverage described the dispute as turning on whether the water caused "this specific type" of kidney cancer.
4. Epidemiology. Justice Department lawyers have relied on a federal cancer-incidence study that did not find a statistically significant increase in kidney cancer at Camp Lejeune compared with Camp Pendleton. Plaintiffs counter with ATSDR research associating Camp Lejeune contaminants with kidney cancer.

The government also told the court, according to Roll Call, that Mousser's prognosis is "excellent." That point serves the damages argument rather than causation: a plaintiff expected to do well needs less future care and loses less earning capacity than one facing recurrence.

It is worth being precise about the legal frame. The government is not arguing that TCE cannot cause kidney cancer; it has accepted that it can. Its argument is that the plaintiff must still show, under Section 804(c) of the Honoring our PACT Act, that the relationship between his exposure and his harm is sufficient to conclude a causal relationship is "at least as likely as not." That equipoise standard is easier than ordinary tort law, but it still requires admissible expert testimony on General Causation and Specific Causation, and the court has held that Rule 702 applies in full.

How much is Frank Mousser asking for in the Camp Lejeune trial?

Frank Mousser is asking for nearly $1.2 million in economic damages — including $802,874 for future medical care and $305,101 for lost earning potential — plus non-economic damages for pain, suffering and loss of enjoyment of life, according to Roll Call and AboutLawsuits. The Lawsuit Information Center puts the economic total at $1,170,829.

Those numbers are modest by the standards of headline personal injury verdicts, and that is deliberate. Three features of the statute compress Camp Lejeune damages.

• No punitive damages. The Camp Lejeune Justice Act bars Punitive Damages, so the award is limited to compensatory damages. In ordinary product cases, punitive awards often account for the largest share of a verdict.
• No jury. A bench trial removes the variance that produces outlier non-economic awards. Judges tend to anchor pain-and-suffering awards to comparable cases.
• Mandatory offsets. Any award must be reduced by related government benefits, discussed in the next section.

The economic figures also show how plaintiffs' counsel built the case. Future care at $802,874 is roughly two-thirds of the economic claim, which means the plaintiff's life-care plan — surveillance imaging, potential treatment for recurrence, and related care — is the heart of the damages presentation. That is also exactly where the government's "excellent prognosis" point and its offset argument both aim. If the court finds the future-care plan overstated, or that much of it will be paid by the VA, Medicare or TRICARE, the economic award could shrink substantially even if the plaintiff wins on causation.

The comparison with the government's own settlement program is instructive. Under the Elective Option, a Tier 1 kidney cancer claimant receives a fixed payment between $150,000 and $450,000 depending on time at the base, without proving causation and without offsets for VA disability benefits. A litigated award that exceeds the Elective Option grid after offsets and fees validates the choice to litigate; one that falls below it would reinforce the government's message that the program is the better deal.

Will VA benefits reduce a Camp Lejeune trial award?

Yes, in part. Section 804 of the Honoring our PACT Act requires that any award to an individual be offset by the amount of any disability award, payment, or benefit provided under certain federal programs — including VA health care and disability compensation, Medicare and Medicaid — in connection with health care or disability relating to exposure to Camp Lejeune water. The fight in Mousser is over how far that offset reaches, and in particular whether benefits that have not yet been paid count.

The Justice Department's position, reported by Roll Call, is that future VA, Medicare, TRICARE and disability benefits should reduce the award, and that plaintiffs are trying to avoid the offset by labeling those future benefits "speculative." The plaintiffs' position is that the statute offsets benefits actually provided, and that a court cannot net out benefits a claimant may or may not receive years from now.

The court has already moved part of the way. In June 2026, according to WFAE and WUNC, the judges held that the government must prove at trial that any VA, Medicare or Medicaid benefits were paid for a condition caused by the water before an offset applies. Mealey's described a companion order as allowing "some" offset of damages. Mousser is the first case in which that framework meets an actual damages record.

Offset issue	Government position	Plaintiff position	Where it stands
Past VA disability compensation for the claimed condition	Offset in full	Offset only if proved related to water exposure	June 2026 order: government bears burden to prove relationship at trial
Past Medicare or Medicaid payments for cancer treatment	Offset	Offset only if proved paid for the water-caused condition	Same June 2026 framework
Future VA, Medicare and TRICARE benefits	Reduce future-care award now	Too speculative to offset	Contested at trial; undecided
Elective Option payments	Not applicable (no trial)	Not applicable	Elective Option offers are not offset by VA disability benefits, per DOJ
Attorney fees	Federal Tort Claims Act caps (20 percent administrative, 25 percent litigated) apply, per DOJ	Disputed by some counsel	Not part of the damages calculation

The practical consequence is easy to state without inventing numbers. A litigated award equals proven compensatory damages, minus offsets the government proves, minus fees and any Medical Lien that must be satisfied. For a veteran with a service-connected disability rating and VA-provided cancer care, the second and third subtractions can be large. That is the government's main lever for narrowing the gap between trial outcomes and its Elective Option grid, and it is why the first Camp Lejeune trial verdict will be read for its offset analysis as closely as for its causation finding.

Camp Lejeune trial verdict timing: when will Judge Boyle rule in the Mousser case?

Judge Boyle has not indicated when he will rule in Mousser, and no deadline governs his decision. In a federal bench trial, the judge typically takes the case under advisement at the close of evidence, often orders the parties to submit proposed findings of fact and conclusions of law, and then issues a written opinion. In a case with competing epidemiology, dose reconstruction, a contested diagnosis and statutory offsets, a decision weeks or months after the close of evidence would be ordinary.

Federal Rule of Civil Procedure 52 governs what that decision must contain and what can happen after it.

Step	Rule	What it means in Mousser
Findings and conclusions	Rule 52(a)(1)	The court must find the facts specially and state its conclusions of law separately, in an opinion or memorandum or on the record
Judgment on partial findings	Rule 52(c)	A party may ask for judgment on an issue once the other side has been fully heard on it; a docket entry on such a motion appeared October 27, outcome unreported
Deference on appeal	Rule 52(a)(6)	Findings of fact are set aside only if clearly erroneous, with due regard for the trial judge's opportunity to judge witness credibility
Motion to amend findings	Rule 52(b)	Due within 28 days after entry of judgment
Motion for new trial	Rule 59	Also due within 28 days after entry of judgment
Notice of appeal	Federal Rule of Appellate Procedure 4(a)(1)(B)	60 days after entry of judgment, because the United States is a party
Appellate court	28 U.S.C. § 1291	U.S. Court of Appeals for the Fourth Circuit

Two points in that table matter more than the rest. First, Rule 52(a)(6) deference means that whatever Judge Boyle finds about Mousser's dose, diagnosis and prognosis will be hard to overturn on appeal. The losing side's appellate arguments will focus on legal questions — how to read "at least as likely as not," whether the ATSDR models can support an individual dose opinion, and whether future benefits are offsettable — rather than on the weighing of evidence.

Second, the 60-day appeal window and the Fourth Circuit's calendar mean a final, appellate answer on those legal questions is unlikely before late 2027. That timing pressure is a central reason both sides prefer a negotiated framework to waiting for Mousser to run its full course.

There is one other possibility. The court could hold its decision while settlement negotiations proceed, or the parties could settle the individual case before a ruling. Neither has been reported. Absent either, the decision will be the first judicial application of Section 804(c) to a full trial record.

Did Camp Lejeune reach a global settlement by October 30?

No global settlement was announced by October 30, 2026, according to every report reviewed for this article through November 2. Coverage published on October 29 said significant disagreements remained over the scope of a possible settlement and the evidence plaintiffs would have to provide, and no subsequent report of a framework, term sheet or joint filing announcing a deal has surfaced.

The target came from an order entered June 30, 2026, directing the Plaintiffs' Leadership Group and the Justice Department to use their best efforts to reach a global settlement by October 30 and to meet weekly with court-appointed settlement masters until then. It was a case management target, not a statutory deadline: no claimant's rights expired on October 30, and the parties were not ordered to settle — only to try.

The court did attach stakes. Summaries of the June order report that if no agreement was reached by the end of October, the court would evaluate whether a restructuring of plaintiffs' leadership was necessary, and some commentators read the order as exposing government counsel to sanctions if the Justice Department did not engage in good faith. Those consequences were softened in advance by a September 29, 2026 order that, according to multiple reports, found progress toward a global settlement was being made and reappointed plaintiffs' leadership through October 30, 2027. Some summaries describe the reappointment differently, but the weight of reporting supports the 2027 date.

The negotiation did not stall for lack of contact. It stalled — at least past the target — over the denominator and the evidentiary bar: how many claimants have which diseases, and what each must show to be paid.

What happens now that the October 30 Camp Lejeune deadline has passed?

Now that the October 30 Camp Lejeune deadline has passed without an announced deal, the court's attention turns to three decisions that will shape any framework: whether to grant the government's Lone Pine motion, whether to order the plaintiffs' 25-condition census, and how to use the Track 1 trial results. Settlement-master sessions are confidential and can continue without a public deadline, so the absence of an announcement does not mean talks have ended.

The competing proposals were both filed in the week before trial, and the plaintiffs answered the government on October 28.

	Government: Lone Pine Order	Plaintiffs' Leadership Group: 25-condition census
Filed	Memorandum filed October 23, 2026	Motion filed October 23, 2026
What it would require	Each plaintiff to show exposure, diagnosis and causation; reports describe expert causation reports for diseases outside the conditions in ATSDR's 2017 assessment	Counsel to report each claimant's name, last four Social Security digits, administrative claim number and diagnosed disease, across 25 conditions
Stated purpose	Manage thousands of suits and hundreds of thousands of claims; government says more than three-quarters of reviewed claims lack documentation	Produce the claimant count needed to negotiate a global resolution
Other side's response	PLG on October 28: motion is "absurd," would delay the case by years or decades and sharply raise costs (Law360)	Government has questioned the scope of the list; the court has not approved the 25 conditions as settlement categories
Status	Undecided	Undecided

The two proposals are not opposites so much as rival sequences. The census counts first and prices later; the Lone Pine Order screens first and counts only what survives. A court could combine them — order a census now and reserve a targeted Lone Pine requirement for diseases outside a negotiated framework or for claimants who opt out of it. That hybrid has been used in other mass tort settings, and it would let the court respond to the passing of the target without choosing a side outright. This newsroom's earlier analysis of the Lone Pine motion sets out the case law.

Beyond those motions, the court has several other levers it can pull after October 30:

• Leadership review. Although the September 29 order reappointed plaintiffs' leadership through October 2027, the court retains authority to restructure appointments at any time.
• More trials. Additional Track 1 trials increase the information available to both sides and the cost to the government of delay. Fancher is already set for November 9.
• Status reports. The court can require more detailed joint reporting on settlement progress, including disease-by-disease positions.
• Targeted rulings. Decisions on the remaining Track 1 Daubert Challenge motions and on offsets give both sides firmer inputs.

Politics also hovers. On October 20 President Trump told a Greenville rally that the Justice Department would settle all remaining legitimate Camp Lejeune claims if Republicans kept control of Congress in the November 3 midterm elections, as this newsroom reported. The election is tomorrow. Nothing in the court's schedule depends on it, but the government's negotiating posture after November 3 is a variable both sides are watching.

When is the next Camp Lejeune trial?

The next Camp Lejeune trial is Fancher, a second kidney cancer case brought by David Fancher, set to begin on November 9, 2026, also as a bench trial before Judge Boyle. Coverage on October 26 reported three more Track 1 trials scheduled after Mousser, with the next in November. The Track 1 leukemia and non-Hodgkin lymphoma cases have been assigned to Judge James C. Dever III.

Date	Event
August 10, 2022	Camp Lejeune Justice Act signed as Section 804 of the Honoring our PACT Act
February 2024	Eastern District of North Carolina holds there is no jury-trial right against the United States under the Act
July 2024	25 Track 1 Trial Plaintiffs selected across five diseases
August 10, 2024	Window to file administrative claims closes
June 2026	Orders on causation, Rule 702 and offsets; June 30 order sets October 30 settlement target
September 29, 2026	Order finds settlement progress, reappoints plaintiffs' leadership
October 19, 2026	Justice Department motions attack individual use of ATSDR models
October 23, 2026	Government Lone Pine memorandum; PLG 25-condition census motion
October 26, 2026	Mousser trial opens in Elizabeth City
October 27, 2026	Docket entry on motion for judgment on partial findings (outcome unreported)
October 28, 2026	Mousser evidence closes; PLG opposes Lone Pine motion
October 30, 2026	Global settlement target passes; no deal announced
November 3, 2026	Midterm elections
November 9, 2026	Fancher kidney cancer bench trial scheduled before Judge Boyle

The decision to try a second kidney cancer case immediately after the first is significant. If Fancher presents a different diagnosis profile — for example, renal cell carcinoma rather than a urothelial cancer — the two judgments together would show how the court treats the diagnosis question that the government has pressed. Two kidney cancer decisions from the same judge within weeks would also give the parties a much firmer basis for valuing the kidney cancer tier of any Settlement Matrix than a single result could.

Does the Mousser verdict affect my Camp Lejeune claim?

The Mousser verdict will not decide any other claimant's case and will not bind any other judge, but it will influence the value of every similar claim. It is a single-plaintiff judgment, not a class ruling, and Mousser is not a Bellwether Trial in the formal sense of a sample whose result is extrapolated by agreement. Its effect will run through information and, if appealed, through precedent.

Concretely, a decision will tell claimants and their lawyers three things.

How the court reads "at least as likely as not." The first written application of the equipoise standard to a full evidentiary record will show how much weight the court gives to population-level studies, to the ATSDR models, and to a plaintiff's own exposure history. Every later claimant relies on the same evidence.

How offsets work in practice. Whether future benefits can be netted out of a future-care award matters most to long-serving veterans with high disability ratings, who are a large share of the claimant pool. A ruling either way will change the arithmetic of the choice between litigating and accepting an Elective Option payment.

How kidney cancer is defined. If the court treats urothelial cancers in the kidney region differently from renal cell carcinoma, that distinction is likely to appear in any negotiated framework.

For claimants whose cases are not in Track 1, the most immediate effect is on timing. A favorable ruling for the plaintiff increases pressure on the government to offer broader terms; a defense ruling strengthens its argument for stricter documentation. Either way, the outcome feeds into the Global Settlement talks rather than producing payments directly.

What the Camp Lejeune trial verdict means for practitioners

For claimants' counsel. The close of the first Camp Lejeune trial without a ruling, and the passing of October 30 without a deal, mean firms should assume documentation requirements will tighten whatever happens next. Whether the court adopts a census, a Lone Pine Order, or a hybrid, firms that already hold medical records confirming diagnosis, records establishing time at the base, and a clear benefits history will move faster. The Mousser damages presentation — a life-care plan carrying most of the economic claim — is also a template: future-care evidence is where the government's prognosis and offset arguments land, and it needs to be built to survive both.

For lien resolution and claims administration. The offset fight is a lien problem in another form. Section 804 offsets operate on the gross award before a Medical Lien is satisfied, and the June 2026 ruling puts the burden on the government to prove which benefits relate to the water-caused condition. Administrators and lien resolution firms will need disease-specific benefit histories, not totals, to model net recoveries under any framework. A ruling that future benefits are offsettable would make that modeling harder and the net figures smaller.

For litigation funders. Funders that have advanced money against Camp Lejeune inventories are exposed to three variables now in play: the per-claim value implied by the first trial results, the proportion of claims that survive a documentation screen, and timing. The passing of the target without a deal extends the duration risk. Any Third-Party Litigation Funding arrangement priced on a 2026 resolution should be revisited against a 2027 horizon.

For the government. The Justice Department's strategy — contest causation in individual trials, press offsets, and screen the inventory through a Lone Pine Order — is coherent, but it carries risk. A plaintiff's judgment in Mousser would undercut the dose argument for the whole kidney cancer tier, and a Lone Pine Order would expose the government to the plaintiffs' charge, now on the record, that it is delaying justice for an elderly and ill claimant pool. The more than $879 million paid as of September 18, overwhelmingly through the Elective Option, is a fraction of an inventory of roughly 408,000 administrative claims and 3,796 lawsuits.

For the court. The court has shown it will use deadlines to force engagement and will soften them when engagement occurs. With October 30 behind it, the most likely next steps are rulings on the competing census and Lone Pine proposals, continued settlement-master sessions, and the Fancher trial — which together create a fresh set of pressure points without a single cliff-edge date.

FAQ

Is there a verdict in the first Camp Lejeune trial?

No. The Mousser v. United States bench trial ended on October 28, 2026, and Judge Terrence W. Boyle has not issued a decision or announced when he will. The outcome will come as a written opinion with findings of fact and conclusions of law, not as a jury verdict.

How much is Frank Mousser asking for in the Camp Lejeune trial?

Mousser's lawyers put his economic damages at nearly $1.2 million — $802,874 for future care and $305,101 for lost earning potential, with one tracker listing $1,170,829 in total — plus non-economic damages. Punitive damages are not available under the Camp Lejeune Justice Act.

What did the government argue in the first Camp Lejeune trial?

The Justice Department argued that Mousser cannot establish general or specific causation, that he spent significant time away from the base, that his diagnosis is not the kidney cancer type most clearly linked to TCE, and that his prognosis is excellent. It also asked that any award be reduced by past and future VA, Medicare, TRICARE and disability benefits.

Did Camp Lejeune reach a global settlement by October 30?

No global settlement was announced by the October 30, 2026 target, according to all coverage reviewed through November 2. The target was a best-efforts case management goal, and confidential settlement-master sessions can continue after it.

When is the next Camp Lejeune trial?

The next trial, Fancher, a second kidney cancer case, is set to begin on November 9, 2026 as a bench trial before Judge Boyle. More Track 1 trials, including leukemia and non-Hodgkin lymphoma cases before Judge James C. Dever III, are expected to follow.

Does the Mousser verdict affect my Camp Lejeune claim?

The decision will not bind any other claimant, but its findings on causation, offsets and the definition of kidney cancer will shape how the government and plaintiffs' leadership value similar claims in any global framework. Its direct effect on other cases would come only through a Fourth Circuit ruling if the judgment is appealed.

This article is analysis of public reporting and court filings, not legal advice.